Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia

BACKGROUND: While many humanized monoclonal antibodies utilize complement-dependent cytotoxicity, the complement depleting effects of these antibodies and the impact of complement replacement on treatment response are not well-described. METHODS: We conducted a phase 2 trial involving patients with...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Hematol
Huvudupphovsmän: Tuscano, Joseph, Poh, Christina, Rosenberg, Aaron, Jonas, Brian, Abedi, Mehrdad, Barisone, Gustavo, Schwab, Emily, Lundeberg, Kathleen, Kaesberg, Paul
Materialtyp: Artigo
Språk:Inglês
Publicerad: Elmer Press 2020
Ämnen:
Short Communication
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7430864/
https://ncbi.nlm.nih.gov/pubmed/32855756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jh721
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk